BioSpace News Archive

OVAL Phase 3 registration-enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer remains on track in spite of COVID-19, with over 260 patients enrolled; next DSMC review expected 3Q21

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that members of Nurix management team will participate in the following conferences in May

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, reported financial results for the first quarter ended March 31, 2021.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that four abstracts were selected for presentation at the International Society for Bipolar Disorders 2021 Global Annual Conference, which will take place virtually from May 13-15, 2021.

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021

Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science

FIREFLY-1 is designed to support regulatory registration of DAY101 in pediatric low-grade glioma (pLGG), which is the most common form of childhood brain cancer and has no approved therapies DAY101 is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor with demonstrated evidence of anti-tumor activity in pLGG

908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to its MX908 handheld mass spec device including a first-of-its-kind aerosol module to detect and identify aerosolized chemical threats

− Initiates Clinical Study of Biannual Dosing Regimen of Investigational Vutrisiran in hATTR Patients with Polyneuropathy, with Data Expected in 2022 Potentially Supporting sNDA Submission – − Introduces New ATTR Program Aimed at Achieving Annual Dosing Regimen with Highly Potent and Reversible Effects; Expected IND Filing at or Around Year-end 2022 –

StageZero Life Sciences, Ltd., a specialist in PCR testing dedicated to the early detection of multiple disease states through whole blood, announced Rexall as the retail outlet that will distribute its COVID-19 PCR saliva test kits in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario beginning May 5.